# Sandra P. D'Angelo

Source: https://onco.cc/people/sandra-dangelo/  
OnCo record `sandra-dangelo` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led SPEARHEAD-1, the trial that made afami-cel the first engineered TCR T-cell therapy approved for a solid tumour.

## Summary

Sandra D'Angelo was principal investigator of SPEARHEAD-1, which showed the MAGE-A4-directed TCR T-cell therapy afamitresgene autoleucel produces durable responses in synovial sarcoma and led to its 2024 approval, the first engineered T-cell therapy for a solid tumour. She also led the JAVELIN Merkel 200 trial that won avelumab approval in Merkel cell carcinoma and leads cellular therapy trials in sarcoma at MSKCC.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: sarcoma; cell-therapy; tcr-t
- Role: Medical Oncologist, Sarcoma and Melanoma Services, Memorial Sloan Kettering Cancer Center
- Specialisms: Sarcoma; Engineered T-cell therapy; Merkel cell carcinoma; Immunotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=D'Angelo%20SP%5BAuthor%5D%20sarcoma%20afamitresgene

## Connected records

- cancers: [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [MAGE-A4](https://onco.cc/targets/mage-a4/)
- drugs: [Afamitresgene autoleucel](https://onco.cc/drugs/afamitresgene-autoleucel/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- key papers: [SPEARHEAD-1: afamitresgene autoleucel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma](https://onco.cc/key-papers/paper-spearhead-1-lancet-2024/)
- trials: [CheckMate 358](https://onco.cc/trials/checkmate-358/)

---
JSON: https://onco.cc/api/v1/entities/sandra-dangelo.json